JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 131 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $6,000 | -57.1% | 2,000 | 0.0% | 0.00% | – |
Q1 2022 | $14,000 | -17.6% | 2,000 | 0.0% | 0.00% | – |
Q4 2021 | $17,000 | +13.3% | 2,000 | 0.0% | 0.00% | – |
Q3 2021 | $15,000 | +7.1% | 2,000 | 0.0% | 0.00% | – |
Q2 2021 | $14,000 | -33.3% | 2,000 | 0.0% | 0.00% | -100.0% |
Q1 2021 | $21,000 | – | 2,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 4,447,829 | $30,245,000 | 89.29% |
TRV GP III, LLC | 3,048,780 | $20,732,000 | 3.62% |
SILVERARC CAPITAL MANAGEMENT, LLC | 250,644 | $1,704,000 | 0.76% |
PFM Health Sciences, LP | 3,262,833 | $22,187,000 | 0.70% |
Yorktown Management & Research Co Inc | 56,600 | $385,000 | 0.30% |
Sofinnova Investments, Inc. | 624,756 | $4,248,000 | 0.24% |
Omega Fund Management, LLC | 275,513 | $1,873,000 | 0.21% |
PATHWAY CAPITAL MANAGEMENT, LP | 60,279 | $410,000 | 0.16% |
Orbimed Advisors | 2,147,400 | $14,602,000 | 0.15% |
Grace Capital | 18,669 | $127,000 | 0.08% |